Serum endothelial monocyte-activating polypeptide-II: A novel biomarker in patients with non-small-cell lung cancer

Clinical Lung Cancer

Volumn 9, Issue 3, 2008, Pages 166-170

  Sen, Elif ^a   Ulger, Fusun ^a   Kaya, Akin ^a   Akar, Nejat ^a   Gonullu, Ugur ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Antiangiogenic factors; Clinicopathologic features; EMAP II; Thrombospondin

Indexed keywords

ENDOTHELIAL MONOCYTE ACTIVATING POLYPEPTIDE II;

ADULT; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; PROGNOSIS; PROTEIN BLOOD LEVEL; ROC CURVE; SURVIVAL TIME;

EID: 45849092273     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2008.n.025     Document Type: Article

References (35)

1. de Castro Junior G, Puglisi F, de Azambuja E, et al. Angiogenesis and cancer: a crosstalk between basic science and clinical trials (the "do ut des" paradigm). Crit Rev Oncol Hematol 2006; 59:40-50.
2. Dudek AZ, Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest 2005; 23:193-200.
3. Yano S, Matsumori Y, Ikuta K, et al. Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer. Int J Clin Oncol 2006; 11:73-81.
4. Kao J, Ryan J, Brett G, et al. Endothelial monocyte-activating polypeptide II. A novel tumor-derived polypeptide that activates host-response mechanisms. J Biol Chem 1992; 267:20239-47.
5. Kao J, Houck K, Fan Y, et al. Characterization of a novel tumor-derived cytokine. Endothelial-monocyte activating polypeptide II. J Biol Chem 1994; 269:25106-19.
6. Schwarz MA, Kandel J, Brett J, et al. Endothelial-monocyte activating polypeptide II, a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells. J Exp Med 1999; 190:341-54.
7. Berger AC, Alexander HR, Wu PC, et al. Tumour necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumour-derived cytokine endothelial monocyte-activating polypeptide II (EMAP-II). Cytokine 2000; 12:992-1000.
8. Keezer SM, Ivie SE, Krutzsch HC, et al. Angiogenesis inhibitors target the endothelial cell cytoskeleton through altered regulation of heat shock protein 27 and cofilin.Cancer Res 2003; 63:6405-12.
9. Ferrario A, von Tiehl KF, Rucker N, et al Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 2000; 60:4066-9.
10. Schwarz M, Lee M, Zhang F, et al. EMAP II: a modulator of neovascularization in the developing lung. Am J Physiol 1999; 276:365-75.
11. Knies UE, Behrensdorf HA, Mitchell CA, et al. Regulation of endothelial monocyte-activating polypeptide II release by apoptosis. Proc Natl Acad Sci U S A 1998; 95:12322-7.
12. Marvin MR, Libutti SK, Kayton M, et al. A novel tumor-derived mediator that sensitizes cytokine-resistant tumors to tumor necrosis factor. J Surg Res 1996; 63:248-55.
13. Wu PC, Alexander HR, Huang J, et al. In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII). Cancer Res 1999; 59:205-12.
14. Barnett G, Jakobsen AM, Tas M, et al. Prostate adenocarcinoma cells release the novel proinflammatory polypeptide EMAP-II in response to stress. Cancer Res 2000; 60:2850-7.
15. Berger AC, Alexander HR, Tang G, et al. Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis. Microvasc Res 2000; 60:70-80.
16. Murray JC, Symonds P, Ward W, et al. Colorectal cancer cells induce lymphocyte apoptosis by an endothelial monocyte-activating polypeptide-II- dependent mechanism. J Immunol 2004; 172:274-81.
17. Murray JC, Heng YM, Symonds P, et al. Endothelial monocyte-activating polypeptide-II (EMAP-II): a novel inducer of lymphocyte apoptosis. J Leukoc Biol 2004; 75:772-6.
18. Faisal W, Symonds P, Panjwani S, et al. Cell-surface associated p43/endothelial-monocyte-activating-polypeptide-II in hepatocellular carcinoma cells induces apoptosis in T-lymphocytes. Asian J Surg 2007; 30:13-22.
19. Jemal A, Murray T, Ward E, et al Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
20. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
21. Fontanini G, Bigini D, Vignati S, et al. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol 1995; 177:57-63.
22. Kaya A, Ciledag A, Gulbay BE, et al. The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med 2004; 98:632-6.
23. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006; 51:143-58.
24. Park JH, Park KJ, Kim YS, et al. Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 2007; 132:200-6.
25. Yamaguchi M, Sugio K, Ondo K, et al. Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer. Lung Cancer 2002; 36:143-50.
26. Mascaux C, Martin B, Paesmans M, et al. Expression of thrombospondin in non-small cell lung cancer. Anticancer Res 2002; 22(2B):1273-7.
27. Suzuki M, Iizasa T, Ko E, et al. Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. Lung Cancer 2002; 35:29-34.
28. Iizasa T, Chang H, Suzuki M, et al. Overexpression of collagen XVIII is associated with poor outcome and elevated levels of circulating serum endostatin in non-small cell lung cancer. Clin Cancer Res 2004; 10:5361-6.
29. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-55.
30. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710-7.
31. Giaccone G. The potential of antiangiogenic therapy in non-small cell lung cancer. Clin Cancer Res 2007; 13:1961-70.
32. Liu SH, Gottsch JD. Apoptosis induced by a corneal-endothelium derived cytokine. Invest Ophthalmol Vis Sci 1999; 40:3152-9.
33. Wellings RP, Lash GE, Murray JC, et al. Endothelial-monocyte activating polypeptide-2 is increased in pregnancy but is not further increased in preeclampsia. J Soc Gynecol Invest 1999; 6:142-6.
34. van Horssen R, Eggermont AM, ten Hagen TL. Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes. Cytokine Growth Factor Rev 2006; 17:339-48.
35. Tas MP, Houghton J, Jakobsen AM, et al. Cloning and expression of human endothelial-monocyte-activating polypeptide 2 (EMAP-2) and identification of its putative precursor. Cytokine 1997; 9:535-9.